1 asset in Pure Squamous Carcinoma Of The Urothelial Tract

Therapeutic assets addressing Pure Squamous Carcinoma Of The Urothelial Tract, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Pure Squamous Carcinoma Of The Urothelial Tract	National Cancer Institute (NCI)	P2	CCC (53)